Role of APOE and IL18RAP gene polymorphisms in cervical spondylotic myelopathy in Indian population

2019 ◽  
Vol 66 ◽  
pp. 83-86 ◽  
Author(s):  
S. Diptiranjan ◽  
S.M. Harshitha ◽  
M.K. Sibin ◽  
S. Arati ◽  
G.K. Chetan ◽  
...  
Keyword(s):  
Cervical Spondylotic Myelopathy ◽  
Gene Polymorphisms ◽  
Indian Population

scholarly journals CRISPLD2 Gene Polymorphisms with Nonsyndromic Cleft Lip Palate in Indian Population

2020 ◽  
Vol 07 (01) ◽  
pp. 022-025
Author(s):  
Praveen Kumar Neela ◽  
Srinivas Reddy Gosla ◽  
Akhter Husain ◽  
Vasavi Mohan
Keyword(s):  
High Risk ◽  
Gene Polymorphisms ◽  
Cleft Lip ◽  
Indian Population ◽  
High Volume ◽  
Genome Association ◽  
Cleft Lip Palate ◽  
Hardy Weinberg Equilibrium ◽  
Whole Genome Association

AbstractCleft lip palate (CLP) is one of the common congenital anomalies with multifactorial etiology. Many genes are associated with its etiology. In one of the studies CRISPLD2 gene polymorphisms rs1546124, rs4783099, and rs16974880 were reported in the Chinese population. However, its role in the Indian population is not yet studied. Hence, this research was conducted on the Indian population to know the role of these high-risk polymorphisms in patients with nonsyndromic CLP. Following an inclusion and exclusion criteria, 20 multiplex CLP families were selected from a high volume cleft center in India. Genomic DNA was isolated from these families. Single nucleotide polymorphism (SNP) rs1546124, rs4783099, and rs16974880 were analyzed for their association using MassARRAY method. A whole-genome association analysis toolset, PLINK was used for statistical analysis. The polymorphisms followed Hardy–Weinberg equilibrium. None of the polymorphisms showed any significance. Hence the high-risk polymorphisms rs1546124, rs4783099, and rs16974880 are not associated with nonsyndromic CLP in Indian population.

Role of convalescent plasma therapy in new Coronavirus disease (nCOVID-19): A review

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 546-549
Author(s):  
Shweta Dadarao Parwe ◽  
Milind Abhimanyu Nisargandha ◽  
Rishikesh Thakre
Keyword(s):  
Clinical Trial ◽  
Immune Responses ◽  
Indian Population ◽  
Preventive Treatment ◽  
The Body ◽  
Therapeutic Antibodies ◽  
Plasma Therapy ◽  
Host Immune Responses ◽  
Transparent Liquid

Hitherto, there is no proper line of treatment for the new (nCOVID19). The development of unique antiviral drugs has taken precedence. Therapeutic antibodies () will be a significantly beneficial agent against nCOVID-19. Here the host immune responses to new discussed in this review provide strategy and further treatment and understanding of clinical interventions against nCOVID-19. Plasma therapy uses the antibodies found in the blood of people recovering (or convalesced) from an infection to treat infected patients. When an infection occurs, the body begins producing proteins specially made to kill the germ, called antibodies. Those antibodies coat specifically plasma in the blood of survivors, the yellow transparent liquid blood portion for months or even years. research assesses plasma use from Convalescent patients of infected with nCOVID-19 as a possible preventive treatment. But it is not yet recommended as a line of treatment, and it is used as a clinical trial in the new in Indian population.

scholarly journals UCP 2 gene polymorphisms in obesity and diabetes, and the role of UCP 2 in cancer

FEBS Letters ◽  
2019 ◽  
Vol 593 (18) ◽  
pp. 2525-2534 ◽  
Author(s):  
Jinran Li ◽  
Rihua Jiang ◽  
Xianling Cong ◽  
Yunfeng Zhao
Keyword(s):  
Gene Polymorphisms ◽  
Obesity And Diabetes

scholarly journals Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19—The Role of RAGE-RAS Crosstalk

Biomolecules ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 876
Author(s):  
Sara Chiappalupi ◽  
Laura Salvadori ◽  
Rosario Donato ◽  
Francesca Riuzzi ◽  
Guglielmo Sorci
Keyword(s):  
Gene Polymorphisms ◽  
Renin Angiotensin System ◽  
Molecular Target ◽  
Advanced Glycation ◽  
Angiotensin System ◽  
Major Player ◽  
Glycation End Products ◽  
End Products ◽  
And Oxidative Stress

The receptor for advanced glycation-end products (RAGE) is a multiligand receptor with a role in inflammatory and pulmonary pathologies. Hyperactivation of RAGE by its ligands has been reported to sustain inflammation and oxidative stress in common comorbidities of severe COVID-19. RAGE is essential to the deleterious effects of the renin–angiotensin system (RAS), which participates in infection and multiorgan injury in COVID-19 patients. Thus, RAGE might be a major player in severe COVID-19, and appears to be a useful therapeutic molecular target in infections by SARS-CoV-2. The role of RAGE gene polymorphisms in predisposing patients to severe COVID-19 is discussed. 

Association of TLR4 gene polymorphisms with sepsis after a burn injury: findings of the functional role of rs2737190 SNP

2021 ◽  
Author(s):  
Claudia A. Colín-Castro ◽  
Rafael Franco-Cendejas ◽  
Hector I. Rocha-González ◽  
Esteban Cruz-Arenas ◽  
Norberto Leyva-García ◽  
...  
Keyword(s):  
Gene Polymorphisms ◽  
Functional Role ◽  
Burn Injury ◽  
Tlr4 Gene
Sign in / Sign up

Export Citation Format

Share Document